This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahuja, H. G. Articles by Slovak, M. L. Search for Related Content PubMed PubMed Citation Articles by Ahuja, H. G. Articles by Slovak, M. L.

t(9;11)(p22;p15) in Acute Myeloid Leukemia Results in a Fusion between NUP98 and the Gene Encoding Transcriptional Coactivators p52 and p75-Lens Epithelium-derived Growth Factor (LEDGF)¹

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 [H. G. A., J. H.]; Division of Clinical Sciences, National Cancer Institute, Gaithersburg, Maryland 20877 [P. D. A.]; and Departments of Hematology and Bone Marrow Transplantation [S. J. F.] and Cytogenetics [L. T., M. L. S.], City of Hope, National Medical Center, Duarte, California 91010

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
A t(9;11)(p22;p15) chromosomal translocation was identified in an adult patient with de novo acute myelogenous leukemia. Fluorescence in situ hybridization and Southern blot analysis mapped the 11p15 breakpoint to the NUP98 gene. Using 3' rapid amplification of cDNA ends, we have identified a chimeric mRNA that fused the NUP98 FXFG repeats in frame to the COOH-terminal portion of the gene encoding the transcriptional coactivators p52 and p75, also known as lens epithelium-derived growth factor (LEDGF). As expected, both NUP98-p52 and NUP98-p75 (LEDGF) chimeric mRNAs were detected by reverse transcription-PCR; however, the reciprocal p52/p75 (LEDGF)-NUP98 fusion mRNA was not detected. Our results demonstrate that this is the most 5' NUP98 fusion reported and reveal a previously unrecognized genetic target, the gene encoding p52/p75 (LEDGF).

	Introduction

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
The NUP98 gene, localized to chromosome band 11p15, encodes a M_r 98,000 component of the nuclear pore complex. NUP98 appears to function as a docking protein involved in nucleocytoplasmic transport; this docking function is mediated at least in part by multiple FXFG repeats located in the NH₂-terminal portion of the gene (1) . Several recent reports have indicated that NUP98 is rearranged in chromosomal translocations in patients with myelodysplastic syndromes, AML,³ and T-cell acute lymphoblastic leukemia (2, 3, 4, 5, 6, 7, 8) . Chimeric mRNAs generated as a result of translocations involving NUP98 are predicted to encode proteins that fuse the FXFG repeats of NUP98 with the homeodomains of HOXA9, HOXD13, and PMX-1 (all homeodomain-containing proteins); DDX10 (a putative RNA helicase); DNA topoisomerase 1; and RAP1GDS1 [a guanine nucleotide exchange factor (2, 3, 4, 5, 6, 7, 8) ].

t(9;11)(p22;p15) is a rare abnormality that has been reported previously in a patient with a biphenotypic leukemia (9) . Here we describe the molecular characterization of the t(9;11)(p22;p15) chromosomal translocation detected in a patient with AML. We hypothesized that the NUP98 gene would be disrupted and that a chimeric gene fusing the NUP98 FXFG repeats in frame to a gene on chromosome band 9p22 would result.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Case Report.
Patient 96-1322 was a 52-year-old Caucasian male who was diagnosed with AML (French-American-British classification M1). His presentation karyotype was characterized by a 46,XY,t(9;11)(p22;p15). Induction therapy consisted of cytarabine and idarubicin followed by an autologous stem cell transplant using cyclophosphamide, etoposide, and total body irradiation as the conditioning regimen. Interleukin 2 was administered after the transplant. The patient achieved a complete remission; however, he relapsed after 9 months. His karyotype at relapse was essentially unchanged, with the t(9;11)(p22;p15) detected in all 20 metaphases analyzed. Molecular characterization studies were performed on the sample obtained at relapse.

Cytogenetics.
A bone marrow sample was cultured and harvested for classical cytogenetic analysis using standard methods. A 20-cell analysis was done on GTG-banded metaphases. The PACs 1173K (NUP98) and 47G3 (which maps telomeric to 1173K) were labeled with Spectrum Green and Spectrum Red, respectively, by nick translation (Vysis, Downers Grove, IL). Because 47G3 maps telomeric to NUP98 on chromosome 11, translocations involving NUP98 will exhibit a split NUP98 signal with a translocation of the complete 47G3 signal to the derivative chromosome 9. Residual cell pellets were used for FISH analysis following standard procedures. A total of 200 interphase cells were scored.

Nucleic Acid Isolation.
Genomic DNA and RNA were obtained from frozen cell pellets of leukemic cells (4) . Control DNA and RNA were obtained from peripheral blood cells from a normal volunteer. The studies were approved by the Institutional Review Board, and informed consent was obtained for use of patient materials in research studies

Southern Blots and Probes.
Southern blots were performed as described previously (7) . Probe A was a 1.24-kb EcoRI-HindIII NUP98 cDNA fragment encompassing nucleotides 1–1248 (exons 1–9 and a portion of exon 10). Probe B was a 1.4-kb HindIII-EcoRV fragment encompassing nucleotides 1249–2628 (a portion of exon 10 and exons 11–19) of the NUP98 cDNA fragment (GenBank accession number U41815) and was a kind gift from Dr. Julian Burrow (Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA; Fig. 1B ).

View larger version (38K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. A, FISH analysis of a t(9;11)(p22;p15) sample. The NUP98 clone was labeled with Spectrum Green, and the more telomeric 4FG3 probe was labeled with Spectrum Red. The t(9;11)(p22;p15) rearrangement (inset) resulted in a split NUP98 signal on der(11) (upper left in the metaphase cell; arrow in the interphase cell). The segment distal to the NUP98 breakpoint, containing the remainder of the NUP98 signal and the distal 4FG3 signal, has been translocated to the derivative 9 chromosome at band 9p22. Inset, GTG-banded chromosome 9 and 11 pairs. The right chromosome of each pair is involved in t(9;11)(p22;p15). Breaks have occurred in bands 9p22 and 11p15. The segments distal to these two breakpoints have been exchanged. B, map of the human NUP98 gene obtained by comparing the NUP98 cDNA sequence with that obtained from a human PAC clone (RP11-348A20; GenBank accession number AC018803). The size of the introns was derived from plasmid subclones of the NUP98 PAC clone (1173K) and from sequences deposited in GenBank (accession number AC018803). The region of the gene encompassed by probes A and B is shown. The location of the t(9;11) breakpoint in relation to previously reported NUP98 breakpoints is indicated. G, BglII. C, NUP98 gene rearrangements. Southern blots of BglII-digested DNA from the patient sample and control hybridized to probe B (left) and probe A (right) are shown. Size standards are in kb. An identical non-germ-line restriction fragment of 9 kb is seen with both probes.

Reverse Transcription-PCR Analysis.
A NUP98 sense primer (NUP1100) and antisense primers from the unique 3' untranslated regions of gene encoding p52 (911-04; nucleotides 1165–1141; GenBank accession number AF098482) and p75 (LEDGF) (911-03; nucleotides 2039–2015; GenBank accession number AF063020) were used to amplify potential NUP98-p52 and NUP98-p75 (LEDGF) chimeric cDNAs. Similarly, a p52/p75 (LEDGF) sense primer (911-01; nucleotides 40–61; GenBank accession number AF098482) and a NUP98 antisense primer (NUP8006; nucleotides 1981–1957) were used to amplify potential p52/p75 (LEDGF)-NUP98 fusion mRNAs as described previously (7) .

	Results and Discussion

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
FISH analysis revealed a split signal with 1173K, indicating that NUP98 was disrupted as a result on the translocation, and the segment distal, including the more telomeric 47G3 signal, was translocated to the derivative chromosome 9 (Fig. 1A) . To map the breakpoint, we searched for genomic DNA rearrangements within the NUP98 locus by Southern blot hybridization to both probes A and B (Fig. 1B) . As shown in Fig. 1C , a novel BglII restriction fragment of approximately 8 kb hybridized to both probes. These results suggested that the most likely site of the breakpoint was a BglII fragment encompassed by both probes A and B. Based on the genomic structure of the NUP98 gene (see Fig. 1B ), we hypothesized that the BglII fragment that included exons 9, 10 ,and 11 was the most likely site of the breakpoint.

We used 3' RACE to identify a potential fusion transcript involving NUP98. Sequence analysis of one of the positive clones revealed that the sequence diverged from the NUP98 cDNA sequence (GenBank accession number U41815) at nucleotide 1230. A BLAST search showed that the sequence 3' of the divergence point was a perfect match for the gene encoding the transcriptional coactivators p52 and p75, also known as lens-epithelium derived growth factor (LEDGF), both of which are derived by alternative splicing of the same gene on chromosome band 9p22 (10) . The resultant in-frame chimeric mRNA joined nucleotide 1230 of NUP98 to nucleotide 534 of the gene encoding p52 (GenBank accession number AF098482), which corresponds to nucleotide 767 of the published sequence for the cDNA encoding p75 (GenBank accession number AF063020; Fig. 2A ). This is the most 5' NUP98 fusion point reported.

View larger version (23K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. A, NUP98-p52/p75 (LEDGF) fusion sequence. The germ-line NUP98 and p52/p75 (LEDGF) nucleotide sequences are shown. The NUP98-p52/p75 (LEDGF) fusion cDNA is indicated. The encoded amino acids are shown below the nucleotide sequence. B, RT-PCR assay for fusion mRNAs. PCR was performed using gene-specific primer pairs for NUP98-p52 (Lanes 1–3) and NUP98-p75 (Lanes 4–6). The PCR products were Southern blotted and probed with a nested oligonucleotide (NUP 911-02; nucleotides 1134–1110; GenBank accession number AF063020). Lanes 1 and 4 represent the patient sample, Lanes 2 and 5 are control cDNAs, and Lanes 3 and 6 represent negative controls with no cDNA. No specific PCR product is seen in the control lanes. Strong hybridizing signals of the expected sizes in Lanes 1 (782 bp) and 4 (1364 bp) indicate the presence of chimeric mRNAs. C, schematic representation of the wild-type and fusion proteins. Arrows indicate the fusion point of NUP98 and p52/p75. Functional domains indicated for NUP98 are as follows: FXFG, FXFG repeat region; and RNA-Bind, RNA-binding domain. The NH2-terminal 325 residues of p52 and p75 are identical. p75 differs from p52 in that it lacks the COOH-terminal 8 residues (derived from intron sequences) and has a unique region of 205 residues at its COOH terminus. The highly conserved HATH region at the NH2 terminus of p52/p75 is shown by the black bar. The striped box in both p52/p75 indicates a highly charged region in the COOH terminus with sequence similarity to HMG-1.

The p52/p75 proteins are homologous to the HDGF and the HDGF-related proteins 1 and 2. The highest degree of sequence identity (80%) is found in the NH₂-terminal 98 amino acid residues, also known as the HATH region (homologous to the NH₂ terminus of HDGF, Fig. 2C ). The COOH-terminal region of p52 (also present in p75) shows similarity to HMG-1, a multifunctional non-histone protein involved in many steps of gene regulation. p52 is a potent general transcriptional coactivator and is thought to mediate functional interactions between upstream sequence-specific activators and the general transcription apparatus (11) . It has also been shown to interact with the essential splicing factor ASF/SF2 to modulate pre-mRNA splicing (12) . p75 is a less potent coactivator than p52 and does not functionally interact with ASF/SF2 (11 , 12) . However, it has been shown to function as a growth and survival factor for lens epithelial cells, keratinocytes, and skin fibroblasts (13) .

The exact mechanism of leukemogenesis remains to be elucidated. One possible scenario is the disruption of functions normally attributable to NUP98 and/or p52/p75. Another scenario is a gain of function attributable to the fusion protein(s). The COOH-terminal region of p52/p75, which has similarity to HMG-1, is preserved in the critical fusion message. However, the NH₂-terminal HATH region is lost and replaced by the NUP98 FXFG repeats (Fig. 2C) , which have been shown to interact with cAMP-responsive element-binding protein and possess strong transactivating properties (14) . This raises the possibility that the fusion proteins are aberrant transcription factors. Finally, the possibility that replacement of the NH₂-terminal HATH sequences by the NUP98 FXFG repeats in p75 results in a fusion protein with deregulated growth-promoting and survival properties must also be considered. The reason for the heterogeneous group of fusion partners remains unknown. They are reminiscent of the various MLL and ETV6 fusions. In all of the reported translocations involving NUP98, the partner genes appear to contribute functionally important domains that are retained in the fusion proteins. It is interesting that three of the reported fusion proteins are homeodomains. It is possible that the other partner genes supply a general function.

In summary, we have cloned t(9;11)(p22;p15) and demonstrated an in-frame fusion between NUP98 and p52/p75 (LEDGF). Future experiments focusing on the structure-function relationships of the p52/p75 (LEDGF) gene and functional analyses of the two fusion proteins will provide new insights into the mechanism of leukemogenesis.

	ACKNOWLEDGMENTS

 
We thank Elena Greco for artwork and Marianne Carr for excellent secretarial assistance.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a grant from the Roswell Park Cancer Institute Alliance Foundation and NIH Grant CA-30206.

² To whom requests for reprints should be addressed. Present address: University of Wisconsin Cancer Center, Wausau Hospital, 215 North 28^th Street, Wausau, WI 54401. Phone: (715) 847-2866; Fax: (715) 847-2869; E-mail: harisha{at}waushosp.org

³ The abbreviations used are: AML, acute myelogenous leukemia; FISH, fluorescence in situ hybridization; RACE, rapid amplification of cDNA ends; HDGF, hepatoma-derived growth factor; PAC, P₁ artificial chromosome.

Received 5/19/00. Accepted 10/ 3/00.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 

1. Borrow, J., Shearman, A. M., Stanton, V. P., Jr., Becher, R., Collins, T., Williams, A. J., Dube, I., Katz, F., Kwong, Y. L., Morris, C., Ohyashiki, K., Toyama, K., Rowley, J., and Houseman, D. E. The t(7;11)(p15;p15) translocation in acute myeloid leukemia fuses the genes for nucleoporin NUP98 to class I homeoprotein HOXA9. Nat. Genet., 12: 159–167, 1996.
2. Nakamura T., Largaespada D. A., Lee M. P., Johnson L. A., Ohyashiki K., Toyama K., Chen S. J., Willman C. L., Chen I-M., Feinberg A. P., Jenkins N. A., Copeland N. G., Shaughnessy J. D. Fusion of the nucleoporin gene NUP98 to HOXA9 by chromosomal translocation t(7;11)(p15;p15) in human myeloid leukemia. Nat. Genet., 12: 154-158, 1996.[Medline]
3. Raza-Egilmez S. Z., Jani-Sait S. N., Grossi M., Higgins M. J., Shows T. B., Aplan P. D. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res., 58: 4269-4273, 1998.[Abstract/Free Full Text]
4. Nakamura T., Yamazaki Y., Hatano Y., Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood, 94: 741-747, 1999.[Abstract/Free Full Text]
5. Arai Y., Hosoda F., Kobayashi H., Kyoko A., Hayashi Y., Nanao K., Kaneko Y., Ohki M. The inv(11)(0p15Q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene NUP98 with the putative RNA helicase gene DDX10. Blood, 89: 3936-3944, 1997.[Abstract/Free Full Text]
6. Ahuja H. G., Felix C. A., Aplan P. D. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood, 94: 3258-3261, 1999.[Abstract/Free Full Text]
7. Hussey D. J., Nicola M., Moore S., Peters G. B., Dobrovic A. The t(4;11)q21;p15) translocation fuses the NUP98 and RAPIGDSI genes and is recurrent in T-cell acute lymphocytic leukemia. Blood, 94: 2072-2079, 1999.[Abstract/Free Full Text]
8. Radu A., Moore M. S., Blobel G. The peptide repeat domain of nucleoporin NUP98 functions as a docking site in transport across the nuclear pore complex. Cell, 81: 215-222, 1995.[Medline]
9. Ha S. Y., Chan L. C. Biphenotypic leukemia with t(9;11)(p22;p15). Cancer Genet. Cytogenet., 76: 116-117, 1994.[Medline]
10. Singh, D. P., Kimura, A., Chylack, L. T., Jr., and Shinohara, T. Lens epithelium-derived growth (LEDGF/p75) and p52 are derived from a single gene by alternative splicing. Gene (Amst.), 242: 265–273, 2000.
11. Ge H., Si Y., Roeder R. G. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J., 17: 6723-6729, 1998.[Medline]
12. Ge H., Si Y., Wolfe A. P. A novel transcriptional coactivator, p52, functionally interacts with the essential splicing factor ASF/SF2. Mol. Cell, 2: 751-759, 1998.[Medline]
13. Singh, D. P., Ohguro, N., Kikuchi, T., Sueno, T., Reddy, V. N., Yuge, K., Chylack, L. T., Jr., and Shinohara, T. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes and fibroblasts. Biochem. Biophys. Res. Commun., 267: 373–381, 2000.
14. Kasper L. H., Brindle P. K., Schnabel C. A., Pritchard C. E., Cleary M. L., van Deursen J. M. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOX9 oncogenicity. Mol. Cell. Biol., 19: 764-776, 1999.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Liedtke and M. L. Cleary Therapeutic targeting of MLL Blood, June 11, 2009; 113(24): 6061 - 6068. [Abstract] [Full Text] [PDF]

				T. A. Brown-Bryan, L. S. Leoh, V. Ganapathy, F. J. Pacheco, M. Mediavilla-Varela, M. Filippova, T. A. Linkhart, R. Gijsbers, Z. Debyser, and C. A. Casiano Alternative Splicing and Caspase-Mediated Cleavage Generate Antagonistic Variants of the Stress Oncoprotein LEDGF/p75 Mol. Cancer Res., August 1, 2008; 6(8): 1293 - 1307. [Abstract] [Full Text] [PDF]

				M. Daugaard, T. Kirkegaard-Sorensen, M. S. Ostenfeld, M. Aaboe, M. Hoyer-Hansen, T. F. Orntoft, M. Rohde, and M. Jaattela Lens Epithelium-Derived Growth Factor Is an Hsp70-2 Regulated Guardian of Lysosomal Stability in Human Cancer Cancer Res., March 15, 2007; 67(6): 2559 - 2567. [Abstract] [Full Text] [PDF]

				C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer Mol. Cell. Proteomics, October 1, 2006; 5(10): 1745 - 1759. [Abstract] [Full Text] [PDF]

				G. N. Maertens, P. Cherepanov, and A. Engelman Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin J. Cell Sci., June 15, 2006; 119(12): 2563 - 2571. [Abstract] [Full Text] [PDF]

				F. Turlure, G. Maertens, S. Rahman, P. Cherepanov, and A. Engelman A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo Nucleic Acids Res., March 20, 2006; 34(5): 1653 - 1665. [Abstract] [Full Text] [PDF]

				Y.-W. Lin, C. Slape, Z. Zhang, and P. D. Aplan NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia Blood, July 1, 2005; 106(1): 287 - 295. [Abstract] [Full Text] [PDF]

				R. M. Gurevich, P. D. Aplan, and R. K. Humphries NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation Blood, August 15, 2004; 104(4): 1127 - 1136. [Abstract] [Full Text] [PDF]

				Y.-Z. Ge, M.-T. Pu, H. Gowher, H.-P. Wu, J.-P. Ding, A. Jeltsch, and G.-L. Xu Chromatin Targeting of de Novo DNA Methyltransferases by the PWWP Domain J. Biol. Chem., June 11, 2004; 279(24): 25447 - 25454. [Abstract] [Full Text] [PDF]

				I. Lahortiga, J. L. Vizmanos, X. Agirre, I. Vazquez, J. C. Cigudosa, M. J. Larrayoz, F. Sala, A. Gorosquieta, K. Perez-Equiza, M. J. Calasanz, et al. NUP98 Is Fused to Adducin 3 in a Patient with T-Cell Acute Lymphoblastic Leukemia and Myeloid Markers, with a New Translocation t(10;11)(q25;p15) Cancer Res., June 15, 2003; 63(12): 3079 - 3083. [Abstract] [Full Text] [PDF]

				A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al. Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission J. Clin. Oncol., February 15, 2003; 21(4): 615 - 623. [Abstract] [Full Text] [PDF]

				I. Gomes, T. T. Sharma, S. Edassery, N. Fulton, B. G. Mar, and C. A. Westbrook Novel transcription factors in human CD34 antigen-positive hematopoietic cells Blood, June 17, 2002; 100(1): 107 - 119. [Abstract] [Full Text] [PDF]

				R. Rosati, R. La Starza, A. Veronese, A. Aventin, C. Schwienbacher, T. Vallespi, M. Negrini, M. F. Martelli, and C. Mecucci NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15) Blood, May 15, 2002; 99(10): 3857 - 3860. [Abstract] [Full Text] [PDF]

				T. Fujino, A. Suzuki, Y. Ito, K. Ohyashiki, Y. Hatano, I. Miura, and T. Nakamura Single-translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15) Blood, February 15, 2002; 99(4): 1428 - 1433. [Abstract] [Full Text] [PDF]

				T. Taketani, T. Taki, N. Shibuya, E. Ito, J. Kitazawa, K. Terui, and Y. Hayashi The HOXD11 Gene Is Fused to the NUP98 Gene in Acute Myeloid Leukemia with t(2;11)(q31;p15) Cancer Res., January 1, 2002; 62(1): 33 - 37. [Abstract] [Full Text] [PDF]

				H. G.E. Sutherland, G. K. Mumford, K. Newton, L. V. Ford, R. Farrall, G. Dellaire, J. F. Caceres, and W. A. Bickmore Large-scale identification of mammalian proteins localized to nuclear sub-compartments Hum. Mol. Genet., September 1, 2001; 10(18): 1995 - 2011. [Abstract] [Full Text] [PDF]

				R. J. Jaju, C. Fidler, O. A. Haas, A. J. Strickson, F. Watkins, K. Clark, N. C. P. Cross, J.-F. Cheng, P. D. Aplan, L. Kearney, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia Blood, August 15, 2001; 98(4): 1264 - 1267. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahuja, H. G. Articles by Slovak, M. L. Search for Related Content PubMed PubMed Citation Articles by Ahuja, H. G. Articles by Slovak, M. L.